{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:58:47Z","timestamp":1771037927265,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":301,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We compared the 52-week effectiveness and safety of tofacitinib (TOF) and abatacept (ABT) in patients with RA in a real-world setting and investigated a role of human leucocyte antigens (HLA)-DRB1 shared epitope (SE) in the effectiveness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RA patients starting TOF (n\u2009=\u2009187) and ABT (n\u2009=\u2009183) were enrolled. Effectiveness was compared after reducing the selection bias to a minimum using the inverse probability of treatment weighting (IPTW) based on propensity scores. The influence of SE alleles on effectiveness was compared within each treatment group. A treatment group comparison was also performed within SE-positive and SE-negative groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Herpes zoster and some laboratory abnormalities were more frequent in the TOF group than in the ABT group. Patient characteristics did not differ significantly between treatment groups after adjustments with IPTW. The TOF group had a significantly higher proportion of DAS in 28 joints using ESR (DAS28-ESR) remission at week 52 than the ABT group. The DAS28-ESR at week\u00a012 and thereafter was not affected by the copy number of SE alleles in the TOF group, but decreased significantly as the copy number increased in the ABT group. In SE-positive patients, remission and drug retention rates did not differ significantly between the two treatment groups. In SE-negative patients, the TOF group showed significantly higher remission and drug retention rates than the ABT group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The present results suggest that TOF is more effective with regard to remission at week\u00a052 based on treatment responses in SE-negative RA patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkac090","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T13:58:14Z","timestamp":1667051894000},"source":"Crossref","is-referenced-by-count":7,"title":["Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-6951","authenticated-orcid":false,"given":"Wataru","family":"Hirose","sequence":"first","affiliation":[{"name":"Hirose Clinic of Rheumatology , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Zenjinkai Miyazaki-Zenjinkai Hospital , Miyazaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-2983","authenticated-orcid":false,"given":"Kenji","family":"Itoh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, National Defense Medical College , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Aoki Clinic of Rheumatology , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4385-5802","authenticated-orcid":false,"given":"Masahiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, National Defense Medical College , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Nagasawa Clinic of Rheumatology, , Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Komano","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Jujo Takeda Rehabilitation Hospital , Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-074X","authenticated-orcid":false,"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"2022111616101687100_rkac090-B1","doi-asserted-by":"crossref","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis, secondary publication","author":"Kawahito","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2022111616101687100_rkac090-B2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (London)"},{"key":"2022111616101687100_rkac090-B3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"2022111616101687100_rkac090-B4","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"2022111616101687100_rkac090-B5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"2022111616101687100_rkac090-B6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate. Twelve-month data from a twenty-four-month phase iii randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.21876","article-title":"Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a Phase III, international, multicenter, parallel-arm, open-label study","volume":"65","author":"Nash","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2022111616101687100_rkac090-B8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"2022111616101687100_rkac090-B9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-021-02612-w","article-title":"Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis","volume":"23","author":"Hirose","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2022111616101687100_rkac090-B10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.1780301102","article-title":"The shared epitope hypothesis. An approach to understand the molecular genetics of susceptibility to rheumatoid arthritis","volume":"30","author":"Gregersen","year":"1987","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/sarh.2002.32552","article-title":"Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis","volume":"31","author":"Gonzalez-Gay","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.20006","article-title":"Impact of shared epitope genotype and ethnicity on erosive disease. A metanalysis of 3,240 rheumatoid arthritis patients","volume":"50","author":"Gorman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B13","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/art.21385","article-title":"Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated protein","volume":"52","author":"Huizinga","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B14","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2022111616101687100_rkac090-B15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.21739","article-title":"The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis","volume":"54","author":"van der Helm-van Mil","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/rheumatology\/keg190","article-title":"Prospective analysis of the impact of HLA-DR and -DQ on joint destruction in recent-onset rheumatoid arthritis","volume":"42","author":"Wagner","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2022111616101687100_rkac090-B17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-021-02607-7","article-title":"HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA","volume":"23","author":"Rigby","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2022111616101687100_rkac090-B18","first-page":"1234","article-title":"Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis","volume":"77","author":"Oryoji","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022111616101687100_rkac090-B19","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/art.20469","article-title":"The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept","volume":"50","author":"Criswell","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B20","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B21","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept. A phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that indicate twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2022111616101687100_rkac090-B24","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2022111616101687100_rkac090-B25","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med"},{"key":"2022111616101687100_rkac090-B26","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib. Clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022111616101687100_rkac090-B27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/1079990041689665","article-title":"Induction and regulation of IFNs during viral infections","volume":"24","author":"Malmgaad","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"2022111616101687100_rkac090-B28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familiar chilblain lupus due to a gain-of-function mutation in STING","volume":"76","author":"K\u00f6nig","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022111616101687100_rkac090-B29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effect of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2022111616101687100_rkac090-B30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2022111616101687100_rkac090-B31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pst.365","article-title":"Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score","volume":"9","author":"Sugihara","year":"2010","journal-title":"Pharmaceut Statist"},{"key":"2022111616101687100_rkac090-B32","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/ar2975","article-title":"Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor","volume":"12","author":"Balsa","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2022111616101687100_rkac090-B33","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s10067-021-05602-0","article-title":"High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis","volume":"40","author":"Inamo","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2022111616101687100_rkac090-B34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022111616101687100_rkac090-B35","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022111616101687100_rkac090-B36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s10067-019-04449-w","article-title":"Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study","volume":"38","author":"Alten","year":"2019","journal-title":"Clinical Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkac090\/46684197\/rkac090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/6\/3\/rkac090\/47075113\/rkac090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/6\/3\/rkac090\/47075113\/rkac090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T16:10:51Z","timestamp":1668615051000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkac090\/6780004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkac090","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022]]},"published":{"date-parts":[[2022]]},"article-number":"rkac090"}}